期刊文献+

HPLC测定犬血浆中雷诺嗪缓释片的浓度

Determination of Ranolazine in dog plasma by HPLC
原文传递
导出
摘要 目的采用HPLC法测定犬血浆中雷诺嗪缓释片的浓度。方法用乙腈沉淀蛋白,离心后取上清液用氮气吹干,流动相溶解后进行HPLC测定。采用DiamonsilTM C18色谱柱(250mm×4.6mm,5μm)、资生堂MG C18色谱柱(150mm×4.6mm,5μm),流动相为乙腈-水相(7mmol·L-1乙酸铵、3.5mmol·L-1乙酸、1‰三乙胺)(50:50);检测波长230nm;流速0.8mL·min-1;柱温30℃;进样量40μL。犬灌胃给药雷诺嗪缓释片剂量为25mg·kg-1,于不同时间取血,依法测定。结果雷诺嗪的线性范围为0.1~20μg·mL-1(r=0.9998,n=5),高、中、低浓度的日内、日间RSD均小于15%,方法回收率为88%~105%。缓释片和普通片的Cmax分别为1.59±1.07、3.48±2.11μg·mL-1。结论所建方法简便、准确,适用于犬血浆中雷诺嗪的测定及雷诺嗪缓释片的人体药物动力学、生物利用度和生物等效性的研究。雷诺嗪普通片口服吸收快、吸收良好,缓释片无突释现象,具明显缓释作用。 OBJECTIVE To establish an HPLC method for the determination of Ranolazine concentration in dog plasma.METHODS Plasma protein was precipitated by the addition of acetonitrile.The resulting supernatant liquid was dried by nitrogen and was analyzed by the HPLC method after it was diluted quantitatively by mobile phase.C18 column was used.The mobile phase consisted of acetonitrile-water(7 mmol·L^-1 ammonium acetate,3.5 mmol·L^-1 acetic acid and 1‰ triethylamine)(50:50) at flow rate of 0.8 mL·min^-1 and the detective wavelength was 230 nm.RESULTS A good linearity was shown in the range of 0.1-20 μg·mL^-1(r = 0.9998,n = 5).The intra-day RSD and inter-day RSD were less than 15%.The recovery was within 88%-105%.CONCLUSION This method is simple,accurate and applicable to study on pharmacokinetics,bioavailability and bioequiavailability of Ranolazine.
出处 《华西药学杂志》 CAS CSCD 北大核心 2010年第4期456-458,共3页 West China Journal of Pharmaceutical Sciences
关键词 雷诺嗪缓释片 高效液相色谱法 血药浓度 Ranolazine HPLC Blood drug concentration
  • 相关文献

参考文献8

二级参考文献18

  • 1毕惠嫦,关溯,陈孝,齐慧敏,苏启表,黄民.隐丹参酮在小肠吸收机制的实验研究[J].中国临床药理学杂志,2005,21(2):107-110. 被引量:21
  • 2聂淑芳,潘卫三,杨星钢,刘宏飞,刘志东.对大鼠在体肠单向灌流技术中重量法的评价[J].中国新药杂志,2005,14(10):1176-1179. 被引量:90
  • 3胡一桥,郑梁元,钱陈钦,郁伟海.离子型药物酚红的小肠吸收研究[J].中国药科大学学报,1996,27(6):355-359. 被引量:56
  • 4DAVIS SS. Formulation of strategies for absorption windows[ J]. Drug Discov Today, 2005,10 ( 4 ) : 249 - 257. 被引量:1
  • 5ZHAO YH, ABRAHAM MH, LE J, et al. Evaluation of rat intestinal absorption data and correlation with human intestinal absorption [ J ]. Eur J Med Chem ,2003,38 (3) :233 - 243. 被引量:1
  • 6BERLIOZ F, JULIEN S, TSOCAS A, et al. Neural modulation of cephalexin intestinal absorption through the di-and tri peptide brush border transporter of rat jejunum in vivo [ J ]. J Pharmacol Exp Ther,1999,288(3) :1037 - 1044. 被引量:1
  • 7SANDSTROM R, KARLSSON A, LENNERNAS H,et al. The absence of stereo selective P-glycoprotein-mediated transport of R/Sverapamil across the rat jejunum [ J ]. J Pharm Pharmacol, 1998, 50(7) :729 -735. 被引量:1
  • 8[1]Pepine C J, Wolff AA. A controlled trial with a novel anti-ischemic agent, ranolazine, in chromic stable angina pectoris that responsive to conventional antianginal agents. Ranolazine study group [J]. Am J Cardiol , 1999,84: 46-50. 被引量:1
  • 9[2]Bagger JP, Botker HE, Thomassen A, et al. Effects of ranolazine on ischemic threshold coronary sinus blood flow, and myocardial metabolism in coronary artery disease [J]. Cardiovasc Drugs Ther,1997,11:47-84. 被引量:1
  • 10[3]Henon WJ, Eadie J, Penman A D. Estimation of ranolazine and eleven phase I metabolites in human plasma by liquid chromatographyatmospheric pressure chemical ionisation mass spectrometry with selected-ion monitoring[J]. J Chromatogr A, 1995,712: 55-60. 被引量:1

共引文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部